Tarsus Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US87650L1035

SecurityTARS / Tarsus Pharmaceuticals, Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership54,335 shares
Latest Disclosed Value $ 3,811,601
Citigroup Inc ownership in TARS / Tarsus Pharmaceuticals, Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 54,335 shares of Tarsus Pharmaceuticals, Inc. (US:TARS) valued at $3,811,600 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 51,971 shares of Tarsus Pharmaceuticals, Inc.. This represents a change in shares of 4.55% during the quarter. The current value of the position is $3,283,464 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (TARS) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

TARS / Tarsus Pharmaceuticals, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F TARSUS PHARMACEUTICALS COM 87650L103 54,335 2,364 4.55 3,812 -10.43 0.0008
2026-02-13 2025-12-31 13F TARSUS PHARMACEUTICALS COM 87650L103 51,971 11,380 28.04 4,255 76.41 0.0019
2025-11-10 2025-09-30 13F TARSUS PHARMACEUTICALS COM 87650L103 40,591 17,797 78.08 2,412 161.32 0.0011
2025-08-11 2025-06-30 13F TARSUS PHARMACEUTICALS COM 87650L103 22,794 -12,996 -36.31 923 -49.78 0.0005
2025-05-12 2025-03-31 13F TARSUS PHARMACEUTICALS COM 87650L103 35,790 -2,418 -6.33 1,839 -13.10 0.0009
2025-02-12 2024-12-31 13F TARSUS PHARMACEUTICALS COM 87650L103 38,208 4,773 14.28 2,116 92.45 0.0013
2024-11-12 2024-09-30 13F TARSUS PHARMACEUTICALS COM 87650L103 33,435 17,685 112.29 1,100 156.78 0.0006
2024-08-12 2024-06-30 13F TARSUS PHARMACEUTICALS COM 87650L103 15,750 1,628 11.53 428 -16.57 0.0003
2024-05-10 2024-03-31 13F TARSUS PHARMACEUTICALS COM 87650L103 14,122 2,142 17.88 513 111.98 0.0003
2024-02-09 2023-12-31 13F TARSUS PHARMACEUTICALS COM 87650L103 11,980 7,830 188.67 243 231.51 0.0002
2023-12-06 2023-09-30 13F/A-1 TARSUS PHARMACEUTICALS COM 87650L103 4,150 -3,913 -48.53 74 -49.66 0.0001
2023-11-09 2023-09-30 13F TARSUS PHARMACEUTICALS COM 87650L103 4,150 -3,913 74 0.0000
2023-08-10 2023-06-30 13F TARSUS PHARMACEUTICALS COM 87650L103 8,063 7,323 989.59 146 1,511.11 0.0001
2023-05-11 2023-03-31 13F TARSUS PHARMACEUTICALS COM 87650L103 740 -159 -17.69 9 -30.77 0.0000
2023-02-09 2022-12-31 13F TARSUS PHARMACEUTICALS COM 87650L103 899 620 222.22 13 160.00 0.0000
2022-11-10 2022-09-30 13F TARSUS PHARMACEUTICALS COM 87650L103 279 -944 -77.19 5 -72.22 0.0000
2022-08-10 2022-06-30 13F TARSUS PHARMACEUTICALS COM 87650L103 1,223 907 287.03 18 260.00 0.0000
2022-05-12 2022-03-31 13F TARSUS PHARMACEUTICALS COM 87650L103 316 -1,829 -85.27 5 -89.58 0.0000
2022-02-10 2021-12-31 13F TARSUS PHARMACEUTICALS COM 87650L103 2,145 1,183 122.97 48 128.57 0.0000
2021-11-10 2021-09-30 13F TARSUS PHARMACEUTICALS COM 87650L103 962 561 139.90 21 75.00 0.0000
2021-08-10 2021-06-30 13F TARSUS PHARMACEUTICALS COM 87650L103 401 -12 -2.91 12 -7.69 0.0000
2021-05-13 2021-03-31 13F TARSUS PHARMACEUTICALS COM 87650L103 413 -738 -64.12 13 -72.92 0.0000
2021-02-11 2020-12-31 13F TARSUS PHARMACEUTICALS COM 87650L103 1,151 1,151 48 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2024-08-12 2024-06-30 13F TARSUS PHARMACEUTICALS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-05-10 2024-03-31 13F TARSUS PHARMACEUTICALS COM Call 23,000 836 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.